Moderna Expands Horizons With Vertex and Chiesi Deals
Pacts Come Ahead Of R&D Day
Executive Summary
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
You may also be interested in...
Can Moderna Repeat COVID-19 Success In Influenza Market?
The company could have a significant competitive position thanks to the ability to rapidly develop and combine vaccines using mRNA technology.
Chiesi Keen To Nurture Disruptive Innovation
Chiesi may not be a big pharma giant but it is very good at spotting early-stage innovative projects and partnering with the likes of Moderna, Protalix and Bioasis to tackle respiratory and rare diseases, CEO Ugo Di Francesco tells Scrip.
Vertex Inks RNA Splicing Pact With Skyhawk
In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.